Late-breaking data presented at af symposium 2025 highlight key boston scientific therapies for management of patients with atrial fibrillation

First phase of advantage af clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the farapulse™ pulsed field ablation system sub-analysis from option clinical trial highlights consistent safety and efficacy outcomes with the watchman flx™ left atrial appendage closure device post cardiac ablation in both concomitant and sequential procedures marlborough, mass. , jan. 16, 2025 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced data supporting the use of the farapulse™ pulsed field ablation (pfa) system* and the watchman flx™ left atrial appendage closure (laac) device, respectively, during a late-breaking science session at af symposium 2025.
BSX Ratings Summary
BSX Quant Ranking